Setting 
My Cart
Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Bioactive Compounds

Items 12501-12510 of 13618

Page
per page
  1. Ticagrelor
    B2166 Ticagrelor
    Summary: P2Y12 receptor antagonist
      ≥26.15 mg/mL
  2. PF-05212384 (PKI-587)
    B2179 PF-05212384 (PKI-587)
    Summary: PI3Kα, PI3Kγ and mTOR inhibitor
      insoluble in H2O; insoluble in EtOH; ≥15.4 mg/mL
  3. Aliskiren Hemifumarate
    B2215 Aliskiren Hemifumarate
    Target: Renin
    Summary: renin inhibitor
      ≥58.5 mg/mL
  4. HG-10-102-01
    B1262 HG-10-102-01
     1 Citation
    Target: LRRK2
    Summary: LRRK2 inhibitor
      insoluble in H2O; ≥18.9 mg/mL
  5. ONO-8130
    C5743 ONO-8130
    Summary: orally bioavailable antagonist of the prostaglandin E2 (PGE2) receptor EP
      ≤2 mg/mL
  6. Thyroid Hormone Receptor Antagonist (1-850)
    C3006 Thyroid Hormone Receptor Antagonist (1-850)
    Summary: Thyroid hormone receptor antagonist
      ≤0.5 mg/mL
  7. Z-VAD-FMK
    A1902 Z-VAD-FMK
     236 Citation
    Target: Caspases
    Summary: pan-caspase inhibitor
      ≥23.37 mg/mL
  8. WAY 316606 HCl
    B8302 WAY 316606 HCl
    Summary: sFRP-1 inhibitor
      ≥24.25 mg/mL
  9. Amyloid β-Protein (1-15)
    A1003 Amyloid β-Protein (1-15)
    Summary: Principal component of amyloid
      insoluble in EtOH; ≥182.6 mg/mL
  10. Fmoc-Cl
    A7010 Fmoc-Cl
    Summary: solid phase peptide synthesis
      ≥25.9 mg/mL

Items 12501-12510 of 13618

Page
per page